Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive developments like the collaboration with a major CPG company and Bunge, and revenue growth, there are significant concerns. Financial risks are evident with increased cash utilization and reliance on convertible notes. Operational risks and competitive pressures also loom large. The Q&A section highlighted some positive partnerships but lacked clarity on revenue specifics, adding uncertainty. Overall, these factors balance each other, leading to a neutral sentiment with potential for minor fluctuations in stock price.
Key Financial Performance
Normalized Revenues and Other Income $5.8 million in 2024, up from approximately $1 million in 2023, an increase of $4.8 million year-over-year due to the consolidation of the soy product ingredient business in April 2023.
Normalized Cost of Sales $4.5 million in 2024, up from close to $1 million in 2023, reflecting the revenue growth.
SG&A and R&D Expenses $9.3 million in 2024, up from $6.2 million in 2023, an increase of $3.1 million year-over-year, primarily due to non-cash items such as depreciation, amortization, equity incentives, and the consolidation of the soy ingredient business.
Cash Utilization in Operating Activities $9.3 million in 2024, up from $7.5 million in 2023, an increase of $1.8 million year-over-year, with approximately $4 million attributed to lower accounts payable related to transaction costs in 2023.
Cash Position Approximately $5.4 million as of Q4 2024, bolstered by the purchase of 15,000 tons of HB4 soybean through a convertible note to BIOX, covering projected raw material needs until approximately December 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Glaso: Glaso is targeted for commercialization in fiscal year 2025, with expectations to generate new revenues. It is a fat-based product with applications in dietary supplements, nutritional beverages, and pet food.
Piggy Sooy: Piggy Sooy has received USDA approval, allowing for transport and distribution with individual APHIS permits, significantly accelerating logistics and reducing costs.
USDA Approval: Moolec became the first company in its industry to receive USDA approval for Piggy Sooy, providing a distinct market advantage.
Offtake Agreement: Moolec signed a three-year offtake agreement with a major global CPG company for Glaso, expected to generate significant revenue in fiscal year 2025.
Moolabs: Moolec established its fully owned plant molecular biology lab, Moolabs, in Texas, enhancing R&D capabilities and operational efficiencies.
Field Trials: Field trials for Piggy Sooy have commenced in Ohio, Missouri, and Iowa to increase seed production and collect regulatory data.
R&D Collaboration: Moolec signed an R&D collaboration agreement with Bunge to develop safflower varieties, enhancing productivity and expanding market opportunities.
Operational Hub: Moolec plans to establish a new operational hub in the U.S. to strengthen team collaboration and enhance efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Moolec has achieved USDA approval for its Piggy Sooy product, which poses no greater plant pest risk than non-generic soybeans. However, ongoing regulatory approvals from the US FDA are still required, indicating potential delays or challenges in the regulatory pathway.
Supply Chain Challenges: The company has contracted 600 acres for Glaso seed production and is preparing for the commercialization of its products. However, the need to reserve part of the production for seed multiplication may limit immediate sales opportunities.
Competitive Pressures: Moolec's Glaso product competes with established oils like borage and primrose, which have lower GLA concentrations. The company must effectively communicate its competitive advantages to capture market share.
Financial Risks: Moolec's cash position is approximately $5.4 million, and cash utilization has increased, indicating potential financial strain as the company scales operations and invests in R&D.
Market Adoption Risks: The company operates on a B2B model and must effectively educate potential customers about its technology to drive adoption. There is a risk that the market may not fully understand or accept the new products.
Economic Factors: The company is navigating a challenging market environment, which may impact investor interest and overall business growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercialization of Glaso: Expected to generate new revenues in fiscal year 2025, with a focus on textured soy protein and Glaso as a strategic product.
R&D Collaboration with Bunge: Agreement to develop safflower varieties aimed at improving productivity for specific applications and markets.
Regulatory Pathway Progress: Active pursuit of relevant processes and approvals from regulatory agencies for product development.
Expansion of Sales and Marketing: Methodical expansion of the team to capture market opportunities and increase visibility in the industry.
Operational Hub Establishment: New operational hub in the U.S. to enhance collaboration and efficiency.
Revenue Expectations for FY2025: Projected revenues of approximately $6 million from soy protein ingredient business, with Glaso expected to contribute around 15% of total revenue.
Future Revenue Growth: Glaso anticipated to grow significantly in fiscal years 2026 and 2027, becoming a more substantial part of total revenue.
Cash Position: Cash position of approximately $5.4 million as of Q4 2024, with strategic purchases to ensure raw material stability.
Cost Management: Continued focus on evaluating spending and improving cost efficiency.
Production Yields: Expected yields of 50 to 70 tons of GLA from safflower, with ongoing efforts to optimize production.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Offtake Agreement for Glaso: Moolec has signed a three-year offtake agreement with a major global CPG company for Glaso, which is expected to generate new revenues starting in fiscal year 2025.
Revenue Expectations for Glaso: For fiscal year 2025, Glaso is expected to contribute approximately 15% to total revenues, with expectations for growth in subsequent years.
Cash Position and Investments: As of Q4 2024, Moolec's cash position is approximately $5.4 million, which includes the purchase of 15,000 tons of HB4 soybean through a convertible note.
Commercialization Plans: Moolec plans to commercialize Glaso in fiscal year 2025, with a focus on expanding sales and marketing efforts.
Future Revenue Growth: The company anticipates that Glaso will significantly increase its revenue contribution in fiscal years 2026 and 2027.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the collaboration with the major global CPG company for Glaso? What efforts have both parties made, and what is the estimated scale and expected revenue generation in 2025?
A:We are very excited about this offtake agreement with a major global CPG company, which we cannot name due to privacy. This is a three-year contract with the possibility to expand it. We have over 600 acres planted in Idaho, expecting yields similar to last year, around 1,400 tons per acre. We anticipate producing between 50 to 70 tons of GLA for the first year, mostly dedicated to this contract.
Q:Can you share more details about the partnership with Bunge and the business opportunities from this?
A:We are very excited about the R&D collaboration with Bunge, focusing on safflower for biofuel applications and improving safflower varieties. This partnership allows us to enhance our genetic potential and produce products at a larger scale more efficiently.
Q:What steps have you taken to drive awareness and adoption of your PMF products?
A:We focus on educating R&D departments of potential customers and attending industry shows to raise awareness. We aim to communicate our milestones effectively to attract more interest.
Q:How much revenue growth is expected in 2025 for safflower oil products?
A:For fiscal year 2025, we expect Glaso to participate in overall total revenue by around 15%. We anticipate that Glaso will grow significantly in the following years.
Q:What are the specific plans for marketing campaigns and public relations?
A:We plan to continue working with ICR for investor relations and attend more conferences to raise awareness. We aim to communicate our milestones effectively to attract more interest.
Q:How can Glaso be competitive from a cost point of view compared to palm oil?
A:Glaso is not competing with palm oil but with other GLA oils in the market. Our oil produces three times more GLA per kilo than other oils rich in GLA, which is our main competitive advantage.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the estimated scale and expected revenue generation for Glaso in 2025, stating they are in good conversations with potential customers but did not disclose any concrete figures. Additionally, they did not clarify the exact steps they will take to drive awareness and adoption of PMF products, only mentioning general strategies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Arun
Chief Technology
GLA
ICR
RD collaboration
Salinas
United States
acre
advantage
agreement CPG
application
approval
breeding
commodity group
communication
contract
conversation
crop
detail
effort
field trial
floor
front
future
investor
molecule
offtake agreement
organization
productivity
reason
revenue
safflower variety
sale
sample
show
stream
traction
trait
volume
yield
MLEC Transcript
Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
Unknown10-2
The earnings call presents a mixed picture. While there are positive developments like the collaboration with a major CPG company and Bunge, and revenue growth, there are significant concerns. Financial risks are evident with increased cash utilization and reliance on convertible notes. Operational risks and competitive pressures also loom large. The Q&A section highlighted some positive partnerships but lacked clarity on revenue specifics, adding uncertainty. Overall, these factors balance each other, leading to a neutral sentiment with potential for minor fluctuations in stock price.
Moolec Science SA (MLEC) Q3 2024 Earnings Call Transcript
Unknown5-30
The earnings call reveals financial strain with increased expenses and limited cash position, despite some revenue growth. Market competition poses challenges, and the Q&A highlights uncertainties in customer commitments and regulatory timelines. Although there are positive developments like USDA approval, the overall sentiment is cautious, with financial and operational risks overshadowing potential gains.
Moolec Science SA (MLEC) Q1 2024 Earnings Call Transcript
Positive12-14
The earnings call reveals a 92% revenue increase, reduced admin expenses, and strong operational cash utilization. Positive developments in R&D, such as high yield and protein expression levels, bolster sentiment. While there are risks like Argentina's economic reforms, the company's limited exposure minimizes impact. The Q&A highlights strategic lab setup, focus on cash flow, and successful field trials, adding to optimism. Overall, the positive financial performance and strategic advancements suggest a likely stock price increase in the coming weeks.
Moolec Science SA (MLEC) Q3 2023 Earnings Call Transcript
Neutral5-31
MLEC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
